<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04241224</url>
  </required_header>
  <id_info>
    <org_study_id>RMS 103</org_study_id>
    <nct_id>NCT04241224</nct_id>
  </id_info>
  <brief_title>A Prospective, Multicenter Atherectomy Study Showing Luminal Gain in Subjects With Peripheral Vascular Blockages</brief_title>
  <official_title>A Prospective, Multicenter Atherectomy Study Showing Luminal Gain in Subjects With Peripheral Vascular Blockages</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ra Medical Systems</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ra Medical Systems</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and effectiveness of the DABRA Laser System in the atherectomy of&#xD;
      peripheral vascular stenoses.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 26, 2020</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Technical Success</measure>
    <time_frame>At Index Procedure</time_frame>
    <description>The Primary Efficacy Endpoint is the mean reduction in percent diameter stenosis in each subject's primary lesion following treatment with the DABRA Laser System and before any other treatment, as assessed by an independent Angiographic Core Laboratory.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Freedom from Major Adverse Events (MAE)</measure>
    <time_frame>30 Days</time_frame>
    <description>Primary safety endpoint is freedom from Major Adverse Events, defined as all-cause mortality, unplanned major target limb amputation (at or above the ankle), clinically driven target limb revascularization (CD-TLR) at 30 Days, as classified by the Clinical Events Committee (CEC).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Target Lesion Revascularization (TLR) at 6 months</measure>
    <time_frame>6 months</time_frame>
    <description>Clinically driven target lesion revascularization (TLR) at 6 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in Residual Diameter Stenosis</measure>
    <time_frame>At Index Procedure</time_frame>
    <description>Incidence of achieving a residual diameter percent stenosis of ≤ 50% in the primary lesion on the day of treatment, prior to any adjunctive therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rutherford Classification</measure>
    <time_frame>30 Days, 6 Months</time_frame>
    <description>Change from baseline in Rutherford Category.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Percent Diameter Stenosis</measure>
    <time_frame>30 Days, 6 Months</time_frame>
    <description>Percent diameter stenosis and change from baseline in percent diameter stenosis as measured by Doppler Ultrasound and assessed by an independent core laboratory.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vessel Patency</measure>
    <time_frame>30 Days, 6 Months</time_frame>
    <description>Vessel patency as measured by Doppler ultrasound and assessed by an independent core laboratory.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Peripheral Arterial Disease</condition>
  <arm_group>
    <arm_group_label>Excimer Laser Photoablation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Device: DABRA Laser System&#xD;
Patients with symptomatic peripheral vascular disease undergoing an endovascular revascularization procedure utilizing the DABRA Laser System.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Atherectomy</intervention_name>
    <description>Endovascular treatment of peripheral arterial disease</description>
    <arm_group_label>Excimer Laser Photoablation</arm_group_label>
    <other_name>DABRA Laser System</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Participants must meet all of the inclusion criteria to participate in this study:&#xD;
&#xD;
        Inclusion Criteria&#xD;
&#xD;
          1. Ability and willingness to give written informed consent and comply with follow-up&#xD;
             requirements&#xD;
&#xD;
          2. PAD with Rutherford Class 2-5&#xD;
&#xD;
          3. Stenotic lesion(s) in the peripheral vasculature&#xD;
&#xD;
          4. Subject is a candidate for atherectomy for infrainguinal peripheral artery disease&#xD;
&#xD;
        Angiographic Inclusion Criteria&#xD;
&#xD;
          1. Target vessel with documented stenosis by angiography ≥70% and ≤100% by angiography&#xD;
             (as determined by Investigator)&#xD;
&#xD;
          2. Target vessel ≤ 3.0 mm in diameter&#xD;
&#xD;
          3. Target Lesion ≤ 25cm in length&#xD;
&#xD;
          4. The lesion to be treated is not severely calcified&#xD;
&#xD;
          5. Untreated ipsilateral iliac stenosis ≤70% (or tortuosity that might prevent advancing&#xD;
             sheath to lesion) as applicable depending on access&#xD;
&#xD;
          6. No use of another atherectomy device in the same procedure&#xD;
&#xD;
          7. Treatment site is not located in a graft&#xD;
&#xD;
          8. Treatment site is not in, or distal to, a previously placed stent&#xD;
&#xD;
          9. No flow limiting dissection proximal, distal, or in the target lesion (prior to the&#xD;
             use of the investigational device)&#xD;
&#xD;
        Participants meeting any of the exclusion criteria at the time of enrollment (index&#xD;
        procedure/ intervention) will be excluded from study participation:&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          1. Age below 22 years&#xD;
&#xD;
          2. Pregnant, breastfeeding, planning to become pregnant. If women of reproductive&#xD;
             capability will be enrolled, status will be assessed via pregnancy testing. Subject&#xD;
             must agree to use effective birth control measures for duration of study. Pregnancy&#xD;
             during study must be reported immediately.&#xD;
&#xD;
          3. Myocardial infarction (MI) ≤ 60 days prior to procedure&#xD;
&#xD;
          4. Cerebrovascular Accident (CVA) ≤ 60 days prior to procedure&#xD;
&#xD;
          5. Endovascular or surgical procedure ≤ 30 Days prior to procedure or a planned&#xD;
             endovascular or surgical procedure within 30 days after the index procedure&#xD;
&#xD;
          6. Disorders or allergies precluding use of radiographic contrast including renal&#xD;
             insufficiency severe enough to contraindicate use of radiographic contrast&#xD;
&#xD;
          7. Subjects in whom anti-platelet, anticoagulant, or thrombolytic therapy is&#xD;
             contraindicated&#xD;
&#xD;
          8. Life expectancy ≤ 12 months&#xD;
&#xD;
          9. Patient is participating in another investigational drug or device study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Athar Ansari, MD</last_name>
    <role>Study Chair</role>
  </overall_official>
  <overall_contact>
    <last_name>David Nguyen</last_name>
    <phone>760-454-9543</phone>
    <email>dnguyen@ramed.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>California Heart &amp; Vascular Clinic</name>
      <address>
        <city>El Centro</city>
        <state>California</state>
        <zip>92243</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kalli Molzahn</last_name>
      <phone>760-353-3222</phone>
      <email>kalli.m@cacardiology.com</email>
    </contact>
    <investigator>
      <last_name>Athar Ansari, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Merced Vein &amp; Vascular Center</name>
      <address>
        <city>Merced</city>
        <state>California</state>
        <zip>95340</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie Goza, RN</last_name>
      <phone>209-723-6882</phone>
      <email>mercedvascularrn@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Mani Nallasivan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Cardiac &amp; Vascular Institute</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandy Knight, RN</last_name>
      <phone>352-375-1212</phone>
      <phone_ext>1324</phone_ext>
      <email>sknight@tcavi.com</email>
    </contact>
    <investigator>
      <last_name>Arthur Lee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vascardio Heart and Vascular Institute</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33013</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>MIMIT Health</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60616</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yasmeen Ahmed, MD</last_name>
      <phone>847-960-5261</phone>
      <phone_ext>756</phone_ext>
      <email>yasmeen.ahmed@mimithealth.com</email>
    </contact>
    <investigator>
      <last_name>Paramjit Chopra, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sameer Ahmed, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MIMIT Health</name>
      <address>
        <city>Glen Ellyn</city>
        <state>Illinois</state>
        <zip>60137</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yasmeen Ahmed, MD</last_name>
      <phone>847-960-5261</phone>
      <phone_ext>756</phone_ext>
      <email>yasmeen.ahmed@mimithealth.com</email>
    </contact>
    <investigator>
      <last_name>Paramjit Chopra, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sameer Ahmed, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Eastlake Cardiovascular</name>
      <address>
        <city>Roseville</city>
        <state>Michigan</state>
        <zip>48066</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rewaa Yas, MD</last_name>
      <phone>586-944-2800</phone>
      <phone_ext>522</phone_ext>
      <email>ryas@eastlakecv.com</email>
    </contact>
    <investigator>
      <last_name>Thomas P. Davis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>South Texas Vascular Institute</name>
      <address>
        <city>Edinburg</city>
        <state>Texas</state>
        <zip>78539</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ralph H Brookshire, MD</last_name>
      <phone>956-322-7662</phone>
      <email>brookshire@stvi.tech</email>
    </contact>
    <investigator>
      <last_name>Ralph H Brookshire, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Laser Surgical Solutions</name>
      <address>
        <city>McAllen</city>
        <state>Texas</state>
        <zip>78501</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>January 22, 2020</study_first_submitted>
  <study_first_submitted_qc>January 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 27, 2020</study_first_posted>
  <last_update_submitted>October 14, 2021</last_update_submitted>
  <last_update_submitted_qc>October 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>lower extremity Peripheral Arterial Disease (PAD)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

